Skip to content

    ALNYLAM PHARMACEUTICALS, INC.

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Trend
    EarningsRevenue
    $494.33M
    $659.83M
    $500.92M
    $593.17M
    $594.19M
    +20.2%
    $773.69M
    +17.3%
    $1.25B
    +149.3%
    $1.10B
    +84.9%
    Strengthening
    Operating Profit
    -$43.44M
    $48.61M
    -$76.91M
    -$105.16M
    $18.08M
    -$16.20M
    -133.3%
    $367.98M
    $131.72M
    Weakening
    Net Profit
    -$65.94M
    -$16.89M
    -$111.57M
    -$83.76M
    -$18.25M
    +72.3%
    -$66.28M
    -292.4%
    $251.08M
    $147.19M
    Weakening
    EPS
    $-0.52
    $-0.13
    $-0.87
    $-0.14
    +73.1%
    $-0.51
    -292.3%
    $1.91
    Weakening
    Other Income
    -$20.15M
    -$59.78M
    -$31.76M
    -$88.80M
    -$20.45M
    -1.5%
    -$19.16M
    +68.0%
    -$129.01M
    -306.2%
    -$9.81M
    +89.0%
    Weakening
    Interest
    $35.25M
    $33.26M
    $34.38M
    $38.97M
    $58.31M
    +65.4%
    $40.25M
    +21.0%
    $44.40M
    +29.2%
    $109.67M
    +181.4%
    Strengthening
    Depreciation
    Profit before Tax
    -$63.59M
    -$11.17M
    -$108.66M
    -$193.96M
    -$2.37M
    +96.3%
    -$35.36M
    -216.6%
    $238.97M
    $121.91M
    Weakening
    MarginsOPM
    -8.8%
    7.4%
    -15.3%
    -17.7%
    3.0%
    -2.1%
    -128.4%
    29.5%
    12.0%
    Weakening
    Tax
    -3.7%
    -51.2%
    -2.7%
    56.8%
    -670.7%
    -18077.0%
    -87.5%
    -70.7%
    -5.1%
    -89.2%
    -20.7%
    -136.5%
    Weakening
    ReturnsROIC
    1.0%
    0.3%
    1.7%
    1.2%
    0.3%
    -72.3%
    1.0%
    +292.4%
    -3.7%
    -325.0%
    -2.2%
    -275.7%
    Weakening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25
    AssetsCash & Equivalents$420.15M$547.18M$496.58M$819.98M$866.39M$812.69M$966.43M$1.66B
    Short-Term Investments
    Total Current Assets$1.20B$1.72B$2.61B$2.81B$2.69B$2.98B$3.30B$4.05B
    Net PP&E$320.66M$646.38M$706.51M$733.63M$738.63M$725.79M$693.93M$708.06M
    Goodwill
    Intangibles
    Total Assets$1.57B$2.40B$3.41B$3.64B$3.55B$3.83B$4.24B$4.97B
    LiabilitiesTotal Current Liabilities$179.49M$352.59M$585.27M$695.71M$767.91M$967.79M$1.19B$1.47B
    Short-Term Debt
    Long-Term Debt$191.28M$675.70M
    Long-Term Leases$276.13M$293.04M$281.35M$261.34M$243.10M$229.54M$225.09M
    Total Liabilities$272.84M$956.44M$2.39B$3.06B$3.70B$4.05B$4.17B$4.18B
    EquityCommon Stock & APIC$1.01M$1.12M$1.16M$1.20M$1.24M$1.26M$1.29M$1.32M
    Retained Earnings-$2.84B-$3.73B-$4.59B-$5.44B-$6.57B-$7.01B-$7.29B-$6.70B
    Total Equity$1.30B$1.44B$1.02B$588.20M-$158.22M-$220.64M$67.09M$789.18M
    HighlightsNet Cash / (Debt)

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25
    ActivitiesCash from Operating-$562.62M-$278.43M-$614.96M-$641.69M-$541.27M$104.16M-$8.31M$524.08M
    Cash from Investing$272.94M-$417.68M-$435.52M-$273.30M$169.35M-$336.35M-$116.84M$436.33M
    Cash from Financing$65.47M$823.18M$994.98M$1.25B$425.75M$172.13M$294.16M-$305.19M
    SummaryCapital Expenditure-$126.89M-$140.16M-$70.36M-$76.37M-$72.06M-$62.21M-$34.28M-$58.70M
    Free Cash Flow-$689.50M-$418.58M-$685.32M-$718.07M-$613.33M$41.95M-$42.59M$465.38M
    FCF Margin-920.5%-190.5%-139.1%-85.0%-59.1%2.3%-1.9%12.5%